Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

70 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety, pharmacokinetics and pharmacodynamics of multiple-ascending doses of the novel glucokinase activator AZD1656 in patients with type 2 diabetes mellitus.
Morrow LA, Leonsson-Zachrisson M, Ericsson H, Wollbratt M, Knutsson M, Hompesch M, Norjavaara E. Morrow LA, et al. Among authors: hompesch m. Diabetes Obes Metab. 2012 Dec;14(12):1114-22. doi: 10.1111/j.1463-1326.2012.01661.x. Epub 2012 Jul 31. Diabetes Obes Metab. 2012. PMID: 22775976 Clinical Trial.
LAPS Insulin115: A novel ultra-long-acting basal insulin with a unique action profile.
Wronkowitz N, Hartmann T, Görgens SW, Dietze-Schroeder D, Indrakusuma I, Choi IY, Park SH, Lee YM, Kwon SC, Kang Y, Hompesch M, Eckel J. Wronkowitz N, et al. Among authors: hompesch m. Diabetes Obes Metab. 2017 Dec;19(12):1722-1731. doi: 10.1111/dom.13006. Epub 2017 Jul 13. Diabetes Obes Metab. 2017. PMID: 28497570
Bimagrumab improves body composition and insulin sensitivity in insulin-resistant individuals.
Garito T, Roubenoff R, Hompesch M, Morrow L, Gomez K, Rooks D, Meyers C, Buchsbaum MS, Neelakantham S, Swan T, Filosa LA, Laurent D, Petricoul O, Zakaria M. Garito T, et al. Among authors: hompesch m. Diabetes Obes Metab. 2018 Jan;20(1):94-102. doi: 10.1111/dom.13042. Epub 2017 Aug 2. Diabetes Obes Metab. 2018. PMID: 28643356 Clinical Trial.
Single-dose euglycaemic clamp studies demonstrating pharmacokinetic and pharmacodynamic similarity between MK-1293 insulin glargine and originator insulin glargine (Lantus) in subjects with type 1 diabetes and healthy subjects.
Crutchlow MF, Palcza JS, Mostoller KM, Mahon CD, Barbour AM, Marcos MC, Xu Y, Watkins E, Morrow L, Hompesch M. Crutchlow MF, et al. Among authors: hompesch m. Diabetes Obes Metab. 2018 Feb;20(2):400-408. doi: 10.1111/dom.13084. Epub 2017 Sep 26. Diabetes Obes Metab. 2018. PMID: 28817223 Free PMC article. Clinical Trial.
Inhibition of fatty acid synthase with FT-4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non-alcoholic fatty liver disease: Results from two early-phase randomized trials.
Beysen C, Schroeder P, Wu E, Brevard J, Ribadeneira M, Lu W, Dole K, O'Reilly T, Morrow L, Hompesch M, Hellerstein MK, Li K, Johansson L, Kelly PF. Beysen C, et al. Among authors: hompesch m. Diabetes Obes Metab. 2021 Mar;23(3):700-710. doi: 10.1111/dom.14272. Epub 2020 Dec 21. Diabetes Obes Metab. 2021. PMID: 33289350 Free PMC article. Clinical Trial.
Tolerability of eptinezumab in overweight, obese or type 1 diabetes patients.
Baker B, Schaeffler B, Hirman J, Hompesch M, Pederson S, Smith J. Baker B, et al. Among authors: hompesch m. Endocrinol Diabetes Metab. 2021 Feb 2;4(2):e00217. doi: 10.1002/edm2.217. eCollection 2021 Apr. Endocrinol Diabetes Metab. 2021. PMID: 33855218 Free PMC article. Clinical Trial.
70 results